Literature DB >> 22469080

Langerhans cells and T cells sense cell dysplasia in oral leukoplakias and oral squamous cell carcinomas--evidence for immunosurveillance.

J Öhman1, B Magnusson, E Telemo, M Jontell, B Hasséus.   

Abstract

Leukoplakias (LPLs) are lesions in the oral mucosa that may develop into oral squamous cell carcinoma (OSCC). The objective of this study was to assess presence and distribution of dendritic Langerhans cells (LCs) and T cells in patients with LPLs with or without cell dysplasia and in oral squamous cell carcinoma (OSCC). Biopsy specimens from patients with leukoplakias (LPLs) with or without dysplasia and oral squamous cell carcinoma (OSCC) were immunostained with antibodies against CD1a, Langerin, CD3, CD4, CD8 and Ki67, followed by quantitative analysis. Analyses of epithelium and connective tissue revealed a significantly higher number of CD1a + LCs in LPLs with dysplasia compared with LPLs without dysplasia. Presence of Langerin + LCs in epithelium did not differ significantly between LPLs either with or without dysplasia and OSCC. T cells were found in significantly increased numbers in LPLs with dysplasia and OSCC. The number of CD4+ cells did not differ significantly between LPLs with and without dysplasia, but a significant increase was detected when comparing LPLs with dysplasia with OSCC. CD8+ cells were significantly more abundant in OSCC and LPLs with dysplasia compared with LPLs without dysplasia. Proliferating cells (Ki67+) were significantly more abundant in OSCC compared to LPLs with dysplasia. Confocal laser scanning microscopy revealed colocalization of LCs and T cells in LPLs with dysplasia and in OSCC. LCs and T cells are more numerous in tissue compartments with dysplastic epithelial cells and dramatically increase in OSCC. This indicates an ongoing immune response against cells with dysplasia.
© 2012 The Authors. Scandinavian Journal of Immunology © 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22469080     DOI: 10.1111/j.1365-3083.2012.02701.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  17 in total

1.  Langerhans Cell Expression in Oral Submucous Fibrosis: An Immunohistochemical Analysis.

Authors:  Bharghavi Narayanan; Malathi Narasimhan
Journal:  J Clin Diagn Res       Date:  2015-07-01

Review 2.  A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.

Authors:  Olivera J Finn
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

3.  Premalignant Oral Lesion Cells Elicit Increased Cytokine Production and Activation of T-cells.

Authors:  Sara D Johnson; Corinne Levingston; M Rita I Young
Journal:  Anticancer Res       Date:  2016-07       Impact factor: 2.480

Review 4.  The dawn of vaccines for cancer prevention.

Authors:  Olivera J Finn
Journal:  Nat Rev Immunol       Date:  2017-12-27       Impact factor: 53.106

5.  A PIK3CA transgenic mouse model with chemical carcinogen exposure mimics human oral tongue tumorigenesis.

Authors:  Melody T Tan; Jean G Wu; Juan Luis Callejas-Valera; Richard A Schwarz; Ann M Gillenwater; Rebecca R Richards-Kortum; Nadarajah Vigneswaran
Journal:  Int J Exp Pathol       Date:  2020-05-21       Impact factor: 1.925

Review 6.  Molecular Insights into Oral Malignancy.

Authors:  Anuja Deshmukh; Karthik Nagaraja Rao; Ripu Daman Arora; Nitin M Nagarkar; Ambesh Singh; Om Shree Shetty
Journal:  Indian J Surg Oncol       Date:  2021-09-11

7.  Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: a preliminary study.

Authors:  Gregory T Wolf; Douglas B Chepeha; Emily Bellile; Ariane Nguyen; Daffyd Thomas; Jonathan McHugh
Journal:  Oral Oncol       Date:  2014-10-03       Impact factor: 5.337

8.  Histopathological characterization of the oral lichenoid disease subtypes and the relation with the clinical data.

Authors:  J Alberdi-Navarro; X Marichalar-Mendia; M-J Lartitegui-Sebastián; M-L Gainza-Cirauqui; M-A Echebarria-Goikouria; J-M Aguirre-Urizar
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2017-05-01

Review 9.  Redirecting the focus of cancer immunotherapy to premalignant conditions.

Authors:  M Rita I Young
Journal:  Cancer Lett       Date:  2017-01-24       Impact factor: 8.679

Review 10.  Microenvironmental regulation of the progression of oral potentially malignant disorders towards malignancy.

Authors:  Ruixue Ai; Yan Tao; Yilong Hao; Lu Jiang; Hongxia Dan; Ning Ji; Xin Zeng; Yu Zhou; Qianming Chen
Journal:  Oncotarget       Date:  2017-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.